Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HIPEC with cisplatin during debulking surgery for ovarian cancer
2018-003680-62Phase 3Active
- Sponsor
- Centre Oscar Lambret
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Disease-free survival. Started Dec 2018; status: active.
02
Drugs
cisplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on 2018-003680-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003680-62.